ArticleJournal of inflammation research2025
The Value of Dynamic of Alkaline Phosphatase and Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Patients with Non-Small Cell Lung Cancer.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, reliable and convenient markers for identifying patients with non-small cell lung cancer (NSCLC) who benefit from neoadjuvant immunochemotherapy remains elusive. Established static biomarkers, such as programmed cell death ligand 1 (PD-L1) expression and tumor mutational burden (TMB), exhibit limitations in capturing dynamic changes in the immune microenvironment and predicting treatment efficacy compared to dynamic biomarkers. This study aims to evaluate the value of dynamic peripheral blood markers in predicting pathological complete response (pCR) and survival outcomes in patients with NSCLC undergoing neoadjuvant immunochemotherapy. Methods: In this retrospective analysis, clinicopathological data, along with baseline and post-treatment laboratory results, were examined from 113 patients with NSCLC who received neoadjuvant immunochemotherapy between October 2019 and April 2023. The least absolute shrinkage and selection operator (LASSO) algorithm was employed to identify candidate dynamic peripheral blood markers, which were then further refined using logistic regression. An integrated nomogram model incorporating the optimal biomarkers was developed to predict individual pCR. Event-free survival (EFS) was analyzed using the Kaplan-Meier method, with comparisons performed via the Log rank test. Results: Dynamic alkaline phosphatase (dALP) and dynamic neutrophil-to-lymphocyte ratio (dNLR) emerged as independent predictors of pCR following neoadjuvant immunochemotherapy, as confirmed by LASSO and multivariate logistic regression. A predictive model, incorporating dNLR, dALP, degree of differentiation, and smoking history, demonstrated strong predictive capability (AUC = 0.745). Internal validation through bootstrapped resampling yielded a mean AUC of 0.728 (95% CI 0.686-0.749). Survival analysis revealed that patients who achieved pCR had significantly better EFS, and those with low dNLR and dALP values exhibited superior EFS compared to the high-value group. Conclusion: The findings indicate that dNLR and dALP can serve as independent predictors of pCR and EFS in patients with NSCLC treated with neoadjuvant immunochemotherapy. The pCR prediction model incorporating these two markers showed excellent predictive performance, providing valuable clinical guidance for selecting patients who are most likely to benefit from neoadjuvant immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.